On November 11, 2026, Andrew Sinclair, Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board, the Audit Committee of the Board (the “Audit Committee”) and the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), effective on November 13, 2026. Dr. Sinclair’s resignation from the Board was not the result of any disagreement with management or the Board or on any matter relating to the Company’s operations, policies or practices. Effective upon Dr. Sinclair’s resignation, the size of the Board will be reduced from seven to six. On November 13, 2026, upon the recommendation of the NCG Committee of the Board, the Board appointed current director Michael Grissinger to serve on the Audit Committee. The Board determined that Mr. Grissinger meets the requirements for independence of audit committee members under the listing standards of The Nasdaq Stock Market and the Securities and Exchange Act of 1934, as amended. Mr. Grissinger was also appointed to serve as chairperson of the NCG Committee.
|
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company focuses on creating "off-the-shelf" cell products derived from unrelated donors, engineered with chimeric antigen receptors (CARs) to facilitate durable activity without inducing graft-versus-host immune responses. Its lead product candidate, prulacabtagene leucel (prula-cel), targets CD20 and is in Phase 1 clinical trials for autoimmune conditions including lupus nephritis, systemic lupus erythematosus, and systemic sclerosis. The company is also advancing ADI-212, a gene-edited candidate targeting prostate-specific membrane antigen for metastatic castration-resistant prostate cancer. Adicet Bio utilizes a manufacturing process that allows for rapid and cost-efficient generation of product candidates, with plans for outpatient administration. The company maintains a license agreement with CRISPR for gene-editing technology. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage adicetbio.com |
| Sector Healthcare | IR page investor.adicetbio.com | |
|
Tags
cell therapy, gamma delta t cells, car-t, autoimmune diseases, oncology, prostate cancer, lupus nephritis, allogeneic therapy, gene editing, prulacabtagene leucel, prula-cel, ADI-001, ADI-212, ADI-270
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 66.842M |
| Market cap (USD) | $ 66.842M |
| P/E | -0.33 |
| PEG | — |
| P/BV | 0.65 |
| P/S | 2.67 |
| P/OCF | -0.83 |
| P/FCF | -0.83 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -67.6% |
| ROI | -96.6% |
| ROIC | -75.7% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 27 |
| Quality score | -50.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 24.99M | 9.73M | — | — | 741.232M | — |
| Net profit | -116.803M | -117.122M | -142.658M | -69.79M | -61.999M | -36.678M | -82.739M | -37.614M | -33.778M |
| Free cash flow | -96.984M | -93.496M | -98.181M | -61.547M | -64.098M | -42.542M | -73.953M | -35.896M | -11.029M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Lease liabilities (USD) | — | — | — | 1.8M | 21.6M | 20.9M | 21M | 20.9M | 17.2M | 14.7M |
| Cash and deposits (USD) | 0.00 | 53.3M | 7.04M | 33.8M | 84.3M | 278M | 258M | 160M | 56.5M | 38.9M |
| Intangible assets (USD) | — | — | — | — | — | 0.00 | — | — | — | — |
| Right-of-use assets (USD) | — | — | — | 1.4M | 23.1M | 20.4M | 20.3M | 17.4M | 14.2M | 10.9M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | — | -11M | -35.5M | -73.7M | -41.6M | -51.1M | -44.8M | -93.7M | -92.4M | -95.2M |
| Purchases of property, plant and equipment (USD) | — | -44,000 | -362,000 | -271,000 | -990,000 | -13M | -16.8M | -4.46M | -1.12M | -1.74M |
| Change in payables (cash effect) (USD) | — | 1.39M | 1.6M | 3.73M | -814,000 | 1.14M | 1.71M | -1.68M | 1.11M | 1.03M |
| Income taxes paid (cash effect) (USD) | — | — | -5.11M | -62,000 | -3,000 | -43,000 | 0.00 | — | — | — |
| Share-based compensation (USD) | — | 470,000 | 2.79M | 3.69M | 5.26M | 12.5M | 17.1M | 20.3M | 22.2M | 14.3M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | -11M | -35.9M | -74M | -42.5M | -64.1M | -61.5M | -98.2M | -93.5M | -97M |
| Income detail | ||||||||||
| Research and development expense (USD) | — | 16.8M | 31.1M | 73.6M | 34.3M | 48.9M | 71.2M | 106M | 99.3M | 99.1M |
| ↳ 5y CAGR | +33.4% | +27.8% | +6.2% | +23.6% | ||||||
| Total comprehensive income (USD) | — | -33.8M | -37.7M | -82.6M | -36.7M | -62M | -69.8M | -143M | -117M | -117M |
| Comprehensive income to owners (USD) | — | -33.8M | -37.7M | -82.6M | -36.7M | -62M | -69.8M | -143M | -117M | -117M |
| Reported | Mar 18, 2019 | Mar 18, 2019 | Mar 12, 2021 | Mar 12, 2021 | Mar 12, 2021 | Mar 15, 2023 | Mar 15, 2023 | Mar 6, 2025 | Mar 6, 2025 | Mar 12, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
November 5, 2026 at 4:10 PM EST
Phase 1 data for prulacabtagene leucel (prula-cel, formerly ADI-001) demonstrated durable responses and a favorable safety profile in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN)
Pivotal LN study startup activities underway; FDA engagement planned in 4Q/2026 to discuss pivotal expansion into lupus patients without nephritis
Regulatory update and 12-month follow-up data from ~22 patients expected in 1Q/2027
U.S. Food and Drug Administration (FDA) clears Investigational New Drug (IND) and grants Fast Track Designation (FTD) to ADI-212 for metastatic castration-resistant prostate cancer (mCRPC); Phase 1 startup activities underway
Building next-generation in vivo CAR-T platform and pipeline across hematologic and solid tumors, with first candidate expected to enter clinic in 2H/2027
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 5, 2026-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today reported financial results and operational highlights for the third quarter ended September 30, 2026.
“The growing body of evidence for prula-cel continues to strengthen our conviction in its potential to generate meaningful, lasting remissions for patients living with SLE, including those with LN and extra renal SLE. The compelling efficacy observed following complete discontinuation of immunosuppressants, together with evidence of a deep immune reset and a favorable safety profile supporting outpatient administration, reinforce the potential for prula-cel to meaningfully change the treatment paradigm for lupus patients,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “With pivotal study startup activities underway in LN and planned FDA discussions regarding potential pivotal expansion to include lupus patients without nephritis, we look forward to providing a regulatory update and additional 12-month follow-up data from approximately 22 patients in the first quarter of 2027 followed by clinical data from our systemic sclerosis cohort in the second quarter. Together with continued progress on ADI-212 and our in vivo CAR-T pipeline, we believe 2027 will be a catalyst-rich year for Adicet.”
Third Quarter 2026 and Recent Operational Highlights:
Autoimmune diseases
-
Prula-cel demonstrated positive safety and efficacy data in Phase 1 trial of patients with SLE with or without LN. In September 2026, the Company announced updated safety and efficacy data from its ongoing Phase 1 study evaluating prula-cel in patients with SLE, with or without LN. As of the August 28, 2026 data cutoff, 22 efficacy-evaluable patients (16 with LN and 6 with extra-renal SLE) had 6 to 21 months of follow-up, including 13 patients with at least 12 months of follow-up. Prula-cel continued to demonstrate positive clinical responses and a favorable safety profile in this heavily pretreated population. At 12 months, 50% of evaluable LN patients achieved a complete renal response and 54% of evaluable patients achieved Definition of Remission in Systemic lupus (DORIS) remission. Patients also demonstrated rapid and sustained reductions in mean Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the Physician’s Global Assessment (PGA). All patients discontinued immunosuppressants, and all but one tapered background steroids to 5 mg or less of prednisone equivalent. Prula-cel was generally well tolerated, with no Grade > 2 cytokine release syndrome (CRS), no immune effector cell-associated neurotoxicity syndrome (ICANS), no immune effector cell-associated hemophagocytic syndrome (IEC-HS), and no graft-versus-host disease (GvHD) observed, supporting the potential for outpatient administration. Biomarker analyses further demonstrated evidence of immune reset, including complete CD19+ B-cell depletion, naïve-dominant B-cell reconstitution, reductions in anti-dsDNA antibodies, and complement recovery.
-
**Prula-cel pivotal LN study start-up activities underway; FDA meeting planned in 4Q/2026 regarding potential pivotal expansion beyond LN; regulatory update and additional 12-month clinical data expected in 1Q/2027.**The Company has initiated start-up activities for a pivotal study in LN. The single-arm study is expected to enroll a double-digit number of patients, with complete renal response at 12 months as the primary efficacy endpoint. Given the high DORIS remission rates reported in the September 2026 clinical data update, the Company plans to engage with the FDA in the fourth quarter of 2026 regarding the potential expansion of its pivotal development program to include lupus patients without nephritis. The Company expects to provide an update on these discussions, as well as additional clinical data from approximately 22 patients with at least 12 months of follow-up, in the first quarter of 2027.
-
**Phase 1 readout of prula-cel in systemic sclerosis (SSc) expected in the second quarter of 2027.**The Company expects to report clinical data evaluating prula-cel in SSc in the second quarter of 2027.
Solid tumor indications
- Phase 1 startup activities underway for ADI-212 in mCRPC following FDA IND clearance and FTD. In August 2026, the FDA cleared the Company’s IND application for ADI-212 in mCRPC, followed by the granting of FTD in September 2026. Phase 1 startup activities are underway, with patient enrollment in mCRPC anticipated in the first quarter of 2027. ADI-212 is designed as an off-the-shelf therapy, featuring multiple platform enhancements by incorporating gene-editing and expression of novel immune-stimulating molecules intended to strengthen anti-tumor potency, including improved antigen engagement, capacity for durable tumor-killing and active modulation of the tumor microenvironment.
In Vivo CAR-T Program and Pipeline
- Progressing a differentiated portfolio of in vivo CAR-T programs designed to address significant unmet needs in both hematologic malignancies and solid tumors. The Company is advancing its in vivo CAR-T platform and pipeline designed to optimize in vivo T-cell transduction and generate highly cytolytic CAR-T therapy. Ongoing preclinical activities include programs targeting multiple myeloma, non-Hodgkin’s lymphoma, and solid tumor indications. Based on progress to date, The Company plans to initiate its first in vivo CAR-T program in the second half of 2027.
Financial Results for Third Quarter 2026:
-
**Research and Development (R&D) Expenses:**R&D expenses were $15.6 million for the three months ended September 30, 2026, compared to $22.9 million during the same period in 2025. Non-cash stock-based compensation expense included in R&D expense was $0.8 million for the third quarter of 2026.
-
**General and Administrative (G&A) Expenses:**G&A expenses were $4.2 million for the three months ended September 30, 2026, compared to $5.1 million during the same period in 2025. Non-cash stock-based compensation expense included in G&A expense was $0.7 million for the third quarter of 2026.
-
**Net Loss:**Net loss was $18.9 million, or a net loss of $1.76 per basic and diluted share for the three months ended September 30, 2026. This net loss includes non-cash charges of $2.7 million that consisted primarily of share-based compensation, depreciation expenses, and noncash lease expense.
-
Cash Position: Cash, cash equivalents and short-term investments were $100.9 million as of September 30, 2026. The Company expects that current cash, cash equivalents and short-term investments as of September 30, 2026, will be sufficient to fund its operating expenses into the second half of 2027.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: clinical development of Adicet’s product candidates, including future plans or expectations for prula-cel in autoimmune diseases and ADI-212 in mCRPC and the potential safety, tolerability and efficacy for prula-cel in the treatment of autoimmune diseases and ADI-212 in mCRPC as well as expectations to achieve a complete immune reset for prula-cel; expectations regarding future alignment with the FDA on regulatory path to approval and discussions to date; timing and success of the Phase 1 clinical trial of prula-cel in multiple autoimmune indications and ADI-212 in mCRPC, including timing and expectations for enrollment and future data releases; expectations regarding the timing and initiation of a pivotal study for prula-cel in SLE patients with or without LN and potential pivotal expansion to include non-renal lupus; expectations regarding FDA engagement in 4Q/2026 regarding expansion into lupus patients without nephritis; expectations regarding prula-cel’s potential to transform treatment for patients with lupus; expectations regarding the suitability of prula-cel for outpatient administration; expectations regarding the scalability of the Company’s off-the-shelf manufacturing platform; expectations regarding the pace of enrollment in the pivotal study for prula-cel in SLE patients with or without LN; estimates for the addressable patient population and commercial opportunity for prula-cel in LN and SLE; the preclinical and clinical development of ADI-212, including the timing of regulatory filings, clinical startup activities, clinical updates and future data releases; as well as the potential for 2027 to be a catalyst-rich year; the timing of initiation of enrollment of a Phase 1 trial for ADI-212 in mCRPC; expectations regarding the potential potency of ADI-212; timing of updates to the Company’s in vivo CAR T platform pipeline; ongoing preclinical programs and activities relating to autoimmune diseases, hematological malignancies and solid tumors; and expectations regarding Adicet’s uses of capital, expenses and financial results, including the expected cash runway.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet’s ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Adicet’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.
| ADICET BIO, INC. |
| Consolidated Statements of Operations and Comprehensive Income |
| (in thousands, except share and per share amounts) |
| (Unaudited) |
| | | | | | | |
| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |
| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Operating expenses: | | | | | | | | | | | | |
| Research and development | | $ | 15,626 | | | $ | 22,853 | | | $ | 51,562 | | | $ | 74,091 | |
| General and administrative | | | 4,170 | | | | 5,099 | | | | 12,105 | | | | 16,137 | |
| Total operating expenses | | | 19,796 | | | | 27,952 | | | | 63,667 | | | | 90,228 | |
| Loss from operations | | | (19,796 | ) | | | (27,952 | ) | | | (63,667 | ) | | | (90,228 | ) |
| Interest income | | | 972 | | | | 1,172 | | | | 3,482 | | | | 4,253 | |
| Interest expense | | | (23 | ) | | | (12 | ) | | | (68 | ) | | | (12 | ) |
| Other expense, net | | | (30 | ) | | | (64 | ) | | | (83 | ) | | | (300 | ) |
| Loss before income tax provision | | | (18,877 | ) | | | (26,856 | ) | | | (60,336 | ) | | | (86,287 | ) |
| Income tax provision | | | (1 | ) | | | — | | | | (144 | ) | | | — | |
| Net loss | | $ | (18,878 | ) | | $ | (26,856 | ) | | $ | (60,480 | ) | | $ | (86,287 | ) |
| Net loss per share, basic and diluted | | $ | (1.76 | ) | | $ | (4.72 | ) | | $ | (5.62 | ) | | $ | (15.10 | ) |
| Weighted-average common shares used in computing net loss per share, basic and diluted | | | 10,745,696 | | | | 5,692,874 | | | | 10,753,547 | | | | 5,713,216 | |
| Other comprehensive income | | | | | | | | | | | | |
| Unrealized loss on treasury securities, net of tax | | | (70 | ) | | | 97 | | | | (277 | ) | | | 40 | |
| Total other comprehensive income | | | (70 | ) | | | 97 | | | | (277 | ) | | | 40 | |
| Comprehensive loss | | $ | (18,948 | ) | | $ | (26,759 | ) | | $ | (60,757 | ) | | $ | (86,247 | ) |
| ADICET BIO, INC. |
| Consolidated Balance Sheets |
| (in thousands, except share and per share amounts) |
| (Unaudited) |
| | | | | | |
| | | September 30, 2026 | | December 31, 2025 | |
| Cash, cash equivalents, and short-term investments in treasury securities | | $ | 100,945 | | | $ | 158,530 | | |
| Working capital | | | 86,446 | | | | 139,395 | | |
| Total assets | | | 128,946 | | | | 192,355 | | |
| Accumulated deficit | | | (675,177 | ) | | | (614,697 | ) | |
| Total stockholders’ equity | | | 102,697 | | | | 159,210 | | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261105996835/en/
Adicet Bio, Inc. Investor and Media Contacts
Anne Bowdidge [email protected]
Penelope Belnap Precision AQ [email protected]
Source: Adicet Bio, Inc.
© 2026 Adicet Bio All rights reserved. Website Design: Hane Chow, Inc.

Privacy Preference Center
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information
Allow All
Manage Consent Preferences
Strictly Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Performance Cookies
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Targeting Cookies
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Cookie List
Clear
checkbox label label
Apply Cancel
Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Reject All
October 30, 2026 at 5:38 PM EDT
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 30, 2026-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on October 30, 2026.
One individual was hired by Adicet in October 2026 and granted new hire non-qualified stock options to purchase 1,500 shares of Adicet’s common stock with an exercise price of $3.42 per share, the closing price of Adicet’s common stock as reported by Nasdaq on October 30, 2026. One-fourth of the shares underlying the employee’s option will vest on the one-year anniversary of the employee’s start date and thereafter the remaining three-fourths of the shares underlying the employee’s option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to the employee will be fully vested on the fourth anniversary of the employee’s start date, subject to the employee’s continued employment with Adicet on such vesting dates.
The above-described award was granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261030405607/en/
Investor and Media Contacts
Anne Bowdidge [email protected]
Penelope Belnap Precision AQ 212-362-1200 [email protected]
Source: Adicet Bio, Inc.
© 2026 Adicet Bio All rights reserved. Website Design: Hane Chow, Inc.

Privacy Preference Center
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information
Allow All
Manage Consent Preferences
Strictly Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Performance Cookies
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Targeting Cookies
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Cookie List
Clear
checkbox label label
Apply Cancel
Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Reject All
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Jul 21, 2020 | Renamed | RESTORBIO, INC. → ADICET BIO, INC. |
ETFs Holding Adicet Bio, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.